Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 3;105(9):1124–1134. doi: 10.1111/cas.12469

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Fig 5 — Vascular endothelial growth factor (VEGF)-targeted therapy in combination with ifosfamide (IFM) and/or a chemokine (C-X-C motif) receptor 4 (CXCR4) inhibitor effectively suppresses synovial sarcoma (SS) tumor growth. (a) Soft agar assay of Yamato-SS cells treated with activated IFM (aIFM). Colonies >200 μm are shown (n = 3; *P < 0.05, **P < 0.005). (b) Soft agar assay of Yamato-SS cells treated with bevacizumab (Bev; 0.2 μg/mL) and/or aIFM (1 μg/mL). Colonies >200 μm are shown (n = 3; *P < 0.05, **P < 0.005). (c) Phase-contrast images of soft agar assay of Yamato-SS cells treated with aIFM and/or Bev. Scale bar = 200 μm. (d) Immunoblot analysis of poly(ADP-ribose) polymerase (PARP) and proliferating cell nuclear antigen (PCNA) signals in Yamato-SS treated with aIFM for 24 h. STS, 0.5 μM staurosporine for 6 h. (e) Mice bearing Yamato-SS were treated with Bev (25 μg/mouse, twice per week) and/or IFM (2 mg/mouse, 3 days, every 3 weeks). Tumor volume was measured weekly for mice treated with PBS (n = 6), Bev (n = 7), IFM (n = 6), and Bev + IFM (n = 7). *P < 0.05. (f) Mice bearing Yamato-SS were treated with pazopanib (Pazo, 30 mg/kg) and/or CXCR4 inhibitor AMD-070 (10 mg/kg). The tumor volumes were measured every week for mice treated with vehicle (n = 5), Pazo (n = 8), AMD-070 (n = 7), and Pazo + AMD-070 (n = 8; *P < 0.05, **P < 0.005). (g) Mice bearing Yamato-SS were treated with Pazo (30 mg/kg) and IFM (2 mg/mouse, 3 days), Pazo (30 mg/kg) and AMD-070 (10 mg/kg), or Pazo (30 mg/kg), IFM (2 mg/mouse, 3 days) and AMD-070 (10 mg/kg). The tumor volumes were measured every week for mice treated with vehicle (n = 6), Pazo + IFM (n = 7), Pazo + AMD-070 (n = 7), and Pazo + AMD-070 (n = 7), and Pazo + IFM + AMD-070 (n = 7; *P < 0.05).